Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGB | P11216 | 8/20 | 0.44 |
| ▸ | PYGL | P06737 | 3/20 | 0.43 |
| ▸ | PYGM | P11217 | 2/20 | 0.43 |
| ▸ | GBA1 | P04062 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8591408 | 1.00 | PYGB (0.44) | PYGBPYGLPYGMGBA1GAA | |
| SCHEMBL5610713 | 1.00 | PYGB (0.44) | PYGBPYGLPYGMGBA1GAA | |
| SCHEMBL28510346 | 1.00 | PYGB (0.44) | PYGBPYGLPYGMGBA1GAA | |
| SCHEMBL30335844 | 1.00 | PYGB (0.44) | PYGBPYGLPYGMGBA1GAA | |
| SCHEMBL6657589 | 1.00 | PYGB (0.44) | PYGBPYGLPYGMGBA1GAA | |
| Hydrochloric Acid SCHEMBL30833067 | 0.98 | PYGB (0.42) | PYGBPYGLPYGMGBA1GAA | |
| SCHEMBL31520861 | 0.93 | PYGB (0.38) | PYGBPYGLPYGMGBA1GAA | |
| SCHEMBL31520885 | 0.93 | PYGB (0.38) | PYGBPYGLPYGMGBA1GAA | |
| SCHEMBL7134097 | 0.93 | PYGB (0.38) | PYGBPYGLPYGMGBA1GAA | |
| SCHEMBL27920926 | 0.93 | PYGB (0.38) | PYGBPYGLPYGMGBA1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113372514-B | Preparation method of concanavalin polymer hydrogel, hydrogel prepared by preparation method and application of hydrogel | 安徽农业大学 | 2022-06-14 | — | — | CN | claimed |
| US-12583889-B2 | Cell penetrating peptides | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2026-03-24 | — | — | US | disclosed |
| US-12503506-B2 | Dual drug antibody-drug conjugates | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2025-12-23 | — | — | US | disclosed |
| US-20250295603-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | OHIO STATE INNOVATION FOUNDATION | 2025-09-25 | — | — | US | disclosed |
| US-12332238-B2 | Extraction and detection of pathogens using carbohydrate-functionalized biosensors | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2025-06-17 | — | — | US | disclosed |
| EP-4456893-A1 | METHODS FOR THE CONJUGATION OF ANTHRACYCLINES TO CARBOHYDRATE POLYMERIC CARRIERS | Navidea Biopharmaceuticals, Inc. (US) | 2024-11-06 | — | — | EP | disclosed |
| EP-4437108-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Ohio State Innovation Foundation (US) | 2024-10-02 | — | — | EP | disclosed |
| US-20230210998-A1 | METHODS FOR THE CONJUGATION OF ANTHRACYCLINES TO CARBOHYDRATE POLYMERIC CARRIERS | SCOTT, JOHN KIM, JR. | 2023-07-06 | — | — | US | disclosed |
| WO-2023092151-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | OHIO STATE INNOVATION FOUNDATION (US) | 2023-05-25 | — | — | WO | disclosed |
| US-20220249681-A1 | DUAL DRUG ANTIBODY-DRUG CONJUGATES | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2022-08-11 | — | — | US | disclosed |
| CN-113372514-B | Preparation method of concanavalin polymer hydrogel, hydrogel prepared by preparation method and application of hydrogel | 安徽农业大学 | 2022-06-14 | — | — | CN | disclosed |
| EP-3986939-A1 | DUAL DRUG ANTIBODY-DRUG CONJUGATES | University of Georgia Research Foundation, Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| US-11261210-B2 | Glycosylated antitumor ether lipids as novel cancer stem cell cytotoxic agents | UNIVERSITY OF MANITOBA (CA) | 2022-03-01 | — | — | US | disclosed |
| CN-112334582-A | Method for producing protein | 花王株式会社 | 2021-02-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11261210-B2 | Glycosylated antitumor ether lipids as novel cancer stem cell cytotoxic agents | UGCG, MCL1, CASP3 | PYGB 3867/4885PYGL 1695/4885PYGM 4071/4885 |
| US-20230210998-A1 | METHODS FOR THE CONJUGATION OF ANTHRACYCLINES TO CARBOHYDRATE POLYMERIC CARRIERS | TOP1, ALG1, GNE | PYGB 1484/4885PYGL 1310/4885PYGM 707/4885 |
| US-12583889-B2 | Cell penetrating peptides | SLC2A3, SLC1A5, SLC2A1 | PYGB 50/4885PYGL 869/4885PYGM 696/4885 |
| US-20250295603-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PSEN2, NLN, PSEN1 | PYGB 11/4885PYGL 967/4885PYGM 308/4885 |
| US-12503506-B2 | Dual drug antibody-drug conjugates | ABCC1, ABCB1, BCR | PYGB 4402/4885PYGL 2423/4885PYGM 4248/4885 |
| US-20220249681-A1 | DUAL DRUG ANTIBODY-DRUG CONJUGATES | ABCC1, ABCB1, BCR | PYGB 4402/4885PYGL 2423/4885PYGM 4248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.